HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

bestatin (ubenimex)

growth inhibitor; RN given refers to ((L-Leu)-(S-(R*,S*)))-isomer; structure

Also Known As:

ubenimex; 3-amino-2-hydroxy-4-phenylbutyryl-L-leucine; bestatin, (D-Leu)-(R-(R*,R*))-isomer; bestatin, (D-Leu)-(R-(R*,S*))-isomer; bestatin, (D-Leu)-(S-(R*,S*))-isomer; bestatin, (L-Leu)-(R-(R*,R*))-isomer; bestatin, (L-Leu)-(R-(R*,S*))-isomer; bestatin, (L-Leu)-(S-(R*,R*))-isomer; bestatin, (L-Leu)-(S-(R*,S*))-isomer, hydrochloride; (3-amino-2-hydroxy-4-phenylbutanoyl)-L-leucine

Networked: 244 relevant articles (35 outcomes, 54 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 10808
  - Branched-Chain Amino Acids: 778
    - Leucine: 3517
      - bestatin: 244
  - Essential Amino Acids: 403
    - Leucine: 3517
      - bestatin: 244

Experts

1.	Xu, Wenfang: 8 articles (12/2015 - 01/2011)
2.	Fang, Hao: 6 articles (06/2013 - 01/2011)
3.	Zhang, Lei: 5 articles (06/2013 - 08/2006)
4.	Wang, Xuejian: 4 articles (12/2015 - 01/2011)
5.	Xu, Wen-Fang: 3 articles (09/2011 - 01/2010)
6.	Terauchi, Mikio: 3 articles (01/2008 - 01/2007)
7.	Kikkawa, Fumitaka: 3 articles (01/2008 - 01/2007)
8.	Shibata, Kiyosumi: 3 articles (01/2008 - 01/2007)
9.	Nawa, Akihiro: 3 articles (01/2008 - 01/2007)
10.	Kajiyama, Hiroaki: 3 articles (01/2008 - 01/2007)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1990 - "Subgrouping of the patient material gave no evidence that the clinical efficacy of bestatin is related to sex, tumor category or malignancy grade." 07/01/1987 - "Values of T cell subsets in cancer patients recovered to the normal levels by Bestatin treatment. " 12/01/2012 - "This study is to investigate the effects of ubenimex on tumor cell invasion and apoptosis, dose relationship and mechanism. " 08/01/2011 - "Our goal in this study was to evaluate LYP as a candidate compound for cancer treatment, beginning by studying its inhibitory effects on tumors and then comparing it to bestatin. " 07/01/1994 - "In the present study, the in vitro effects of ubenimex on the cytotoxic activity of peripheral blood lymphocytes (PBL) and spleen cells of cancer patients and the mechanism of killer cell activation were investigated. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/1986 - "It is concluded that bestatin is useful for prolongation of survival of adult patients with ANLL, making for a longer remission duration especially in elderly patients and with few side effects." 07/01/2012 - "Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study." 01/01/1990 - "Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults." 11/01/1995 - "We encountered a 71-year-old female with acute myelogenous leukemia (AML, M1), who maintained a steady hematological state for 22 months under ubenimex monotherapy. " 11/01/1995 - "[Hematological stability under ubenimex monotherapy in a patient with acute myelogenous leukemia developing marrow karyotypic changes during the course]."
3.	Melanoma (Melanoma, Malignant) 01/01/1985 - "These findings suggest that Bestatin is a very useful agent for treating for stage Ib and II malignant melanomas." 04/01/2006 - "We investigated the effect of three bestatin derivatives on A375 human melanoma cells and in vitro. " 12/08/2004 - "Oral administration of bestatin (100-200 mg/kg/day) was found to significantly inhibit the melanoma cell-induced angiogenesis in a mouse dorsal air sac assay. " 06/01/1985 - "For this reason, the data from phase III studies of Bestatin, including previously reported findings on malignant melanoma, proved Bestatin to be useful in treating stage Ib and II malignant melanoma, but were only suggestive of its potential indication in the treatment of other malignant tumors of the skin. " 04/01/2006 - "In our previous report, bestatin inhibited the tumor cell invasion and the angiogenesis induced by the inoculation of B16-BL6 melanoma cells into mice and capillary formation on human umbilical vein endothelial cells (HUVECs) in vitro. "
4.	Leukemia 01/01/1986 - "The bestatin group tended to achieve a higher rate of reinduction of remission in patients who had recurrence of leukemia. " 07/03/2002 - "Bestatin may be useful for treating patients with leukemia." 11/01/2001 - "We previously reported that the aminopeptidase inhibitor bestatin induced apoptosis in several human leukemia cell lines. " 12/01/1992 - "Immunopotentiation with Ubenimex for prevention of leukemia relapse after allogeneic BMT. " 04/01/1991 - "An interim report suggests that bestatin may induce chronic GVHD and suppress the relapse of leukemia. "
5.	Carcinoma (Carcinomatosis) 04/16/2003 - "We conducted a prospective randomized, double-blind, placebo-controlled trial to determine whether postoperative adjuvant treatment with bestatin could prolong the survival of patients with completely resected stage I squamous-cell lung carcinoma. " 04/16/2003 - "Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma." 01/01/1990 - "Autoradiographic study of tissue distribution of [3H]ubenimex in IMC carcinoma-bearing mice." 06/01/2013 - "In addition, compound 7e also showed better inhibitory activity against APN on human ovary clear cell carcinoma cell ES-2 than bestatin with the IC(50) value to 30.19 ± 1.02 μM versus 60.61 ± 0.1 μM. " 08/01/2011 - "LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin."

Related Drugs and Biologics

1.	bestatin (ubenimex)
2.	CD13 Antigens (Alanine Aminopeptidase)
3.	Bleomycin (Blenoxane)
4.	aminopeptidase B
5.	Protease Inhibitors (Protease Inhibitor)
6.	Picibanil
7.	actinonin
8.	Prostaglandin D2
9.	Levamisole (Decaris)
10.	Immunologic Factors (Immunomodulators)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Intravesical Administration
4.	Injections
5.	Blood Transfusion (Blood Transfusions)